title: Temporary placement of a paclitaxel or rapamycin-eluting stent is effective to reduce stenting induced inflammatory reaction and scaring in benign cardia stricture models.
abstract: OBJECTIVE
  To investigate whether temporary placement of a paclitaxel or rapamycin eluting stent is more effective to reduce stenting induced inflammatory reaction and scaring than a bared stent in benign cardia stricture models.
  
  
  METHODS
  Eighty dog models of stricture were randomly divided into a control group (CG, n=20, no stent insertion), a bare stent group (BSG, n=20), a paclitaxel eluting (Pacl-ESG, n=20) and a rapamycin eluting stent group (Rapa-ESG, n=20), with one-week stent retention. Lower-oesophageal-sphincter pressure (LOSP), 5-minute barium height (5-mBH) and cardia diameter were assessed before, immediately after the procedure, and regularly for 6 months. Five dogs in each group were euthanized for histological examination at each follow-up assessment.
  
  
  RESULTS
  Stent insertion was well tolerated, with similar migration rates in three groups. At 6 months, LOSP and 5-mBH improved in Pacl-ESG and Rapa-ESG compared to BSG (p<0.05), with no difference between Pacl-ESG and Rapa-ESG (p>0.05). Cardia kept more patency in the Pacl-ESG and Rapa-ESG than in BSG (p<0.05). Reduced peak inflammatory reactions and scarring occurred in the Pacl-ESG and Rapa-ESG compared to BSG (p<0.05), with a similar outcome in the Pacl-ESG and Rapa-ESG (p>0.05).
  
  
  CONCLUSIONS
  Paclitaxel or rapamycin-eluting stents insertion led to better outcomes than bare stents in benign cardia stricture models.
authors.affiliation: Department of Radiology, The Tenth Affiliated People's Hospital, Shanghai Tong Ji University Faculty of Medicine, Shanghai, China; Department of Radiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital600 Yi Shan Road, Shanghai, China. chengyingshengradio@hotmail.com.
authors.forename: Lin
authors.initials: L
authors.lastname: Wang
authors.forename: Yue-Qi
authors.initials: YQ
authors.lastname: Zhu
authors.forename: Ying-Sheng
authors.initials: YS
authors.lastname: Cheng
authors.forename: Wen-Guo
authors.initials: WG
authors.lastname: Cui
authors.forename: Ni-Wei
authors.initials: NW
authors.lastname: Chen
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D002299:Cardia; D002921:Cicatrix / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D003251:Constriction, Pathologic / Q000628:therapy; D004195:Disease Models, Animal; D004285:Dogs; D054855:Drug-Eluting Stents / Q000009:adverse effects; D049630:Esophageal Sphincter, Lower / Q000503:physiopathology; D004940:Esophageal Stenosis / Q000628:therapy; D005260:Female; D006801:Humans; D007249:Inflammation / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D008297:Male; D008365:Manometry; D017239:Paclitaxel / Q000008:administration & dosage*; D011897:Random Allocation; D020123:Sirolimus / Q000008:administration & dosage*; D013997:Time Factors
chemical_list: D000903:Antibiotics, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel; D020123:Sirolimus